Cell and Gene Therapy (CGT) Scheduling Software Global Market Report 2026

The cell and gene therapy (CGT) scheduling software market size has grown rapidly in recent years. It will grow from $0.32 billion in 2025 to $0.39 billion in 2026 at a compound annual growth rate (CAGR) of 19.5%. The growth in the historic period can be attributed to increasing development of cell and gene therapies, adoption of digital scheduling tools in clinical workflows, growing focus on patient-centric treatment planning, rising regulatory requirements for CGT tracking, expansion of biotechnology infrastructure.

The cell and gene therapy (CGT) scheduling software market size is expected to see rapid growth in the next few years. It will grow to $0.8 billion in 2030 at a compound annual growth rate (CAGR) of 19.7%. The growth in the forecast period can be attributed to growing deployment of AI-enabled scheduling platforms, increasing integration with cloud-based CGT systems, rising demand for automated workflow and resource management, expansion of tissue engineering applications, increasing need for predictive analytics in therapy administration. Major trends in the forecast period include increasing adoption of cloud-based cgt scheduling software, rising demand for integrated workflow management solutions, growing focus on real-time supply chain coordination, expansion of regulatory compliance and reporting tools, rising implementation of training and support services.

The rising demand for personalized medicine is anticipated to drive the expansion of the cell and gene therapy (CGT) scheduling software market in the coming years. Personalized medicine encompasses treatments and therapies designed specifically for individual patients based on their genetic profile, biomarkers, and particular disease characteristics. This demand is increasing due to advancements in genomic technologies and molecular diagnostics, which enable healthcare providers to customize treatments according to a patient’s genetic information and enhance therapeutic results. Cell and gene therapy (CGT) scheduling software supports personalized medicine by optimizing the coordination of patient-specific manufacturing, treatment schedules, and clinical workflows, ensuring precise, timely, and individualized delivery of therapies tailored to each patient’s genetic profile. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration approved 16 new personalized therapies for rare disease patients in 2023, compared with six in 2022, including seven cancer treatments and three for other diseases and conditions. Consequently, the growing demand for personalized medicine is driving the expansion of the cell and gene therapy (CGT) scheduling software market.

Leading companies operating in the cell and gene therapy (CGT) scheduling software markets are focusing on developing innovative solutions, such as unified digital orchestration platforms, to streamline complex therapy scheduling, enhance real-time supply chain visibility, and improve coordination between manufacturers and healthcare providers. Unified digital orchestration platforms are integrated software systems that coordinate and automate complex workflows such as patient scheduling, manufacturing slots, logistics tracking, and clinical site communication within a single centralized environment. For example, in November 2025, TrakCel Ltd., a UK-based advanced therapy supply chain technology company, launched Cell And Gene Therapy (CGT) Gateway, a digital orchestration platform designed to streamline access to cell and gene therapies for healthcare providers. This platform is a configurable, cloud-based solution that connects treatment centers, manufacturers, and logistics partners within a single digital ecosystem, enabling automated referral management, patient onboarding, and scheduling workflows. The platform enhances transparency through real-time tracking and milestone notifications, supports regulatory compliance with secure data management features, and reduces administrative burden by digitizing communication and documentation processes. It is designed to accelerate therapy access, improve coordination across stakeholders, and minimize delays in time-sensitive autologous and allogeneic treatments.

In March 2023, TrakCel Ltd, a UK-based company specializing in software for the cell and gene therapy (CGT) sector, including comprehensive patient scheduling capabilities, achieved an integration milestone with Lonza to merge CGT manufacturing and orchestration solutions. This partnership aims to optimize cell and gene therapy production and supply chain management by linking TrakCel’s OCELLOS (orchestration of cell and gene therapy logistics and lifecycle operations software) with Lonza’s MODA-ES (modular open digital architecture enterprise solution) manufacturing execution system, enabling seamless data transfer, improved chain of identity and chain of custody tracking, and greater operational transparency. Lonza Group AG is a Switzerland-based contract development and manufacturing organization that focuses on biologics manufacturing, cell and gene therapy production, and advanced pharmaceutical development services.

Major companies operating in the cell gene therapy (CGT) scheduling software market are market are Siemens AG, Deloitte Touche Tohmatsu Limited, Thermo Fisher Scientific Inc., GE Digital LLC, SAP SE, Rockwell Automation Inc., Dassault Systèmes SE, Infor Inc., Aspen Technology Inc., Azenta Life Sciences, Kinaxis Inc., QAD Inc., Bullhorn Inc., Cryoport Inc., MasterControl Inc., TrakCel Ltd., Bluecrux NV, MangoGem S.A., Title21 Health Solutions Inc, Vineti Inc.

North America was the largest region in the cell and gene therapy (CGT) scheduling software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy (cgt) scheduling software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell and gene therapy (CGT) scheduling software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cell and gene therapy (CGT) scheduling software market includes revenues earned by entities through implementation and integration services, cloud hosting and managed services, consulting and customization, and maintenance, support, and training services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cell and gene therapy (CGT) scheduling software refers to specialized digital platforms developed to coordinate and optimize the complex scheduling, monitoring, and management of cell and gene therapy procedures, including patient visits, laboratory activities, and manufacturing schedules. This software supports timely treatment delivery, regulatory adherence, and efficient allocation of resources across clinical and production workflows in CGT operations.

The essential components of cell and gene therapy (CGT) scheduling software include software and services. Software platforms manage and optimize scheduling, resource allocation, and workflow coordination for cell and gene therapy processes. Solutions are provided via cloud-based and on-premises models, with key applications in cell therapy, gene therapy, tissue engineering, and other areas, serving pharmaceutical companies, biotechnology firms, research institutes, hospitals and clinics, and other end-users.

Tariffs on imported software modules, cloud infrastructure, and specialized CGT laboratory equipment are impacting the cell and gene therapy scheduling software market by raising implementation and operational costs. Segments such as cloud-based software platforms and workflow management tools are most affected, particularly in regions like North America, Europe, and Asia-Pacific that rely on imported components and licenses. While tariffs increase costs, they also encourage local software development, foster domestic IT service growth, and drive innovation in cost-effective and compliant CGT scheduling solutions, offering long-term market resilience.

The cell and gene therapy (CGT) scheduling software market research report is one of a series of new reports that provides cell and gene therapy (CGT) scheduling software market statistics, including cell and gene therapy (CGT) scheduling software industry global market size, regional shares, competitors with a cell and gene therapy (CGT) scheduling software market share, detailed cell and gene therapy (CGT) scheduling software market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy (CGT) scheduling software industry. This cell and gene therapy (CGT) scheduling software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.